NEWS FLASH    G5 govs arrive Oyo for Makinde’s campaign
NewsWorld

2023 Nobel Prize for Medicine goes to mRNA Vaccine Scientists

Emeka Kema

Katalin Karikó and Drew Weissman have been awarded the 2023 Nobel Prize in Physiology or Medicine for their groundbreaking work in the creation of mRNA vaccine technology, which allowed for a quick vaccine response to the Covid-19 pandemic. In just the first year of their usage, SARS-CoV-2 vaccinations are credited with preventing the spread of the epidemic and saving between 14.4 million and 19.8 million deaths; mRNA vaccines were crucial to this success.

The prize, among the most prestigious in the scientific world, was selected by the Nobel Assembly of Sweden’s Karolinska Institute medical university and comes with 11 million Swedish crowns (about $1 million) to share between them.

Kariko, a former senior vice president and head of RNA protein replacement at German biotech firm BioNTech, is a professor at the University of Szeged in Hungary and adjunct professor at the University of Pennsylvania.

In an interview after the award, she said her late mother had long speculated that she might win the Nobel – to which she would remind her there was a time when she could not even get a grant for her research.

“She (my mother) said, ‘but you work so hard’. And I told her that many, many scientists work very, very hard,” added Kariko, who was sleeping when she received the call from Stockholm and initially thought it was a joke.

Co-winner Weissman, a professor in vaccine research also at Pennsylvania, said it was a “lifetime dream” to win and recalled working intensely with Kariko – including middle-of-the-night emails as they both suffered disturbed sleep.

“For the 20 years that we worked together, before anybody knew what RNA is or cared, it was the two of us, literally, side by side at a bench working together, talking and discussing new data,” he said in a recording on the Nobel website.

The two laureates in 2005 jointly developed so-called nucleoside base modifications, which stop the immune system from launching an inflammatory attack against lab-made mRNA, previously seen as a major hurdle against any therapeutic use of the technology.

Related Articles

Close